Dengue vaccines: state of the art
- PMID: 20384534
- DOI: 10.1517/13543771003767476
Dengue vaccines: state of the art
Abstract
Importance of the field: Dengue is a significant public health problem transcending geographical boundaries to place nearly 50% of the global population at risk. A vaccine to prevent dengue is an unmet need that should be addressed urgently.
Areas covered in the review: A brief introduction to dengue and a detailed review of the classical and modern approaches being undertaken currently to develop dengue vaccines described in recent patent literature, highlighting the inherent hurdles and challenges.
What the reader will gain: An understanding of the approaches being deployed to develop multiple viral and non-viral vaccine candidates and an appreciation of the complexity of developing dengue vaccines.
Take home message: Live viral vaccines, which have advanced to clinical trials, have revealed new challenges, emphasizing the need to pursue non-viral alternatives simultaneously.
Similar articles
-
Dengue vaccine: opportunities and challenges.IDrugs. 2008 Jan;11(1):42-5. IDrugs. 2008. PMID: 18175262 Review.
-
Next generation dengue vaccines: a review of candidates in preclinical development.Vaccine. 2011 Sep 23;29(42):7276-84. doi: 10.1016/j.vaccine.2011.07.017. Epub 2011 Jul 21. Vaccine. 2011. PMID: 21781998 Review.
-
Unique challenges faced by the clinical evaluation of dengue vaccines.Expert Rev Vaccines. 2011 Feb;10(2):133-6. doi: 10.1586/erv.10.159. Expert Rev Vaccines. 2011. PMID: 21332260 No abstract available.
-
Tropical diseases. Dengue vaccine trial poses public health quandary.Science. 2014 Jul 25;345(6195):367-8. doi: 10.1126/science.345.6195.367. Science. 2014. PMID: 25061184 No abstract available.
-
Review of dengue virus and the development of a vaccine.Biotechnol Adv. 2011 Mar-Apr;29(2):239-47. doi: 10.1016/j.biotechadv.2010.11.008. Epub 2010 Dec 10. Biotechnol Adv. 2011. PMID: 21146601 Review.
Cited by
-
Hospital-based prevalence of malaria and dengue in febrile patients in Bangladesh.Am J Trop Med Hyg. 2012 Jan;86(1):58-64. doi: 10.4269/ajtmh.2012.11-0190. Am J Trop Med Hyg. 2012. PMID: 22232452 Free PMC article.
-
Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris.BMC Biotechnol. 2016 Feb 4;16:12. doi: 10.1186/s12896-016-0243-3. BMC Biotechnol. 2016. PMID: 26847361 Free PMC article.
-
Use of Animal Models in Studying Roles of Antibodies and Their Secretion Cells in Dengue Vaccine Development.Viruses. 2020 Nov 5;12(11):1261. doi: 10.3390/v12111261. Viruses. 2020. PMID: 33167518 Free PMC article. Review.
-
A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.PLoS Negl Trop Dis. 2018 Jan 8;12(1):e0006191. doi: 10.1371/journal.pntd.0006191. eCollection 2018 Jan. PLoS Negl Trop Dis. 2018. PMID: 29309412 Free PMC article.
-
A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture.Virol J. 2015 Feb 8;12:16. doi: 10.1186/s12985-015-0248-x. Virol J. 2015. PMID: 25886260 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
